Our findings show that STS66 is more effective than BMT in inhibiting the activation of NKCC1 protein and reduced NKCC1-mediated Rb+ influx, which hindered the establishment of intracellular ion gradient in cultured glioma cells. This evidence concerns the gene SLC12A2 and central nervous system cancer.